Y-mAbs Therapeutics (YMAB) announced the appointment of Doug Gentilcore as Senior Vice President SVP, Head of DANYELZA Business Unit. Prior to joining Y-mAbs, he served as Chief Commercial Officer and then Chief Executive Officer of ARTMS.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics announces milestones for 2025
- Y-mAbs Therapeutics reports preliminary FY24 revenue $88M, consensus $88.53M
- Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA
- Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
- Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential